Sally is focused on developing preclinical studies for therapeutic programs at Life Edit Therapeutics.
She has six years of experience in developing AAV-based gene therapy approaches for neurodevelopmental disorder.
Sally received PhD in Neuroscience from University of North Carolina at Chapel Hill.
.svg)
.svg)
To rewrite the future by curing disease, making any edit, anywhere.
To pave the way to faster, safer, gene editing therapeutics that cure disease and improve patient lives.
We’re guided by curiosity, rigor, and integrity. We believe in discovery and unlimited potential. We care about science and the lives of patients.
